Our publications, describing studies with the small molecular inhibitor of the cyclolignan family picropodophyllin (PPP) in vitro, showed that selective inhibition of the IGF/IGF-1R pathway by this drug can be achieved with a favorable therapeutic window in MM cell lines and primary cells (61,64,65). The gene discussed is IGF1; the disease is Miyoshi myopathy.